Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 32s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

From Lab to Clinic: Controlled Drug Delivery Mechanisms and Translational Challenges

Pinky Jaiswal[1], Dr. Shaily Chaudhary[1]*, Madhuri Muwel[1], Mahima Fareliya[1], Mahak Dueby[1], Mayuri Mulewa[1], Lucky Dhakad[1], Mohit Choyal[1], Lakhan Nagar[1], Dr. Akash Yadav[2]

[1] Compfeeders Aisect College of Professional Studies, Pharmacy College, Rangwasa, Indore (M.P.), India

[2] IPS Academy College of Pharmacy, Knowledge Village, A.B. Road, Rajendra Nagar, Indore (M.P.), India

[*]**Corresponding author:**

Dr. Shaily Chaudhary

Head & Professor, Compfeeders Aisect College of Professional Studies, Pharmacy College, Rangwasa, Indore (M.P.), India

Email ID: shailychaudhary@gmail.com

Cite this paper as: Pinky Jaiswal, Dr. Shaily Chaudhary, Madhuri Muwel, Mahima Fareliya, Mahak Dueby, Mayuri Mulewa, Lucky Dhakad, Mohit Choyal, Lakhan Nagar, Dr. Akash Yadav, (2025) From Lab to Clinic: Controlled Drug Delivery Mechanisms and Translational Challenges. *Journal of Neonatal Surgery*, 14 (32s), 4008-1019.

ABSTRACT

Controlled drug delivery systems (CDDS) are designed to release therapeutic agents at precise rates, locations, and durations to enhance treatment efficacy and minimize side effects. Traditional drug delivery methods have several limitations, including high dosage frequency, difficulty in dose monitoring, and non-specific administration. CDDS address these issues by ensuring targeted delivery, improved bioavailability, and reduced dosing frequency. Excipients play a crucial role in CDDS, with polymers, lubricants, and binding agents being key components. Polymers, both synthetic and natural, help regulate drug release, enhance stability, and improve patient compliance. CDDS function based on various mechanisms, including dissolution-controlled, diffusion-controlled, and water penetration-controlled systems. Advanced techniques such as nanoparticle-based delivery, osmotic-controlled systems, and biodegradable polymers further enhance drug delivery efficiency. Pharmacokinetics and pharmacodynamics govern drug absorption, distribution, metabolism, and excretion, influencing bioavailability and therapeutic outcomes. Factors such as molecular weight, solubility, partition coefficient, and pKa affect drug performance in controlled formulations. Compared to conventional drug delivery systems, CDDS maintain plasma drug concentration within the therapeutic window, reducing toxicity risks and enhancing patient compliance. Applications of CDDS span multiple medical fields, including chronic disease management, neurological disorders, hormone therapy, cardiovascular treatments, and antibiotic delivery. Emerging technologies such as nano-medicine, microfluidics, molecularly imprinted polymers, CRISPR/Cas9, and quantum sensing are revolutionizing drug delivery. Additionally, advancements in 3D printing enable customized dosage forms tailored to patient needs. Despite these advancements, challenges remain, including potential toxicity, formulation complexity, and high production costs. Future research aims to improve biocompatibility, develop intelligent biomaterials, and refine personalized medicine approaches. The continuous evolution of CDDS holds promise for more effective and patient-friendly therapeutic solutions.

Keywords: *Controlled Drug Delivery Systems, Pharmacokinetics, Pharmacodynamics, 3D Printing, Nanoparticle-Based Delivery*

1. INTRODUCTION

According to the FDA, a drug (API) is a substance recognized in the pharmacopoeia that is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. [1] A controlled drug delivery system is aimed at releasing the correct dose of a therapeutic directly in the desired zone and during the required period of time. These dosage forms have been used since long, but these are found to Have the following limitations.

- The frequency of administration in a day, ‘dosage regimen’ is high.
- It is difficult to monitor the daily-dose; in many cases, it is not exactly maintained.
- There is a greater chance of missing dose.
- Non-specific administration.

- The careful calculation is required to prevent overdosing; it is difficult to calculate.
- The exact dose for a child or elderly patient who should not receive the adult dose.
- The drug goes to non-target cells and can cause damage; orally administered drug must reach circulatory bloodstream every time and pass through the liver. Drug is available in the sites which are not affected.

Low concentrations can be ineffective. After oral administration fraction of the Dose may not be absorbed, a fraction of dose is metabolized; hence, the amount of Drug must be sufficient to elicit its therapeutic action.

Excipients used in controlled drug delivery systems

Excipients are key ingredients in controlled-release formulations. One or more of the excipients that are generally utilized in formulations include: Colorants, suspending agents, binding agents, solvents and lubricants, fragrances, sweetening agents, flavoring agents, solubilizing agents, and antioxidants. [2]

- **Binding Agent**

Binders are chemicals used to make granules more cohesive. This ensures that the tablet remains intact following compression. The researchers are still interested in developing new excipients for usage as binding agents in tablet formulations.

Example: - Starch, HPMC, Sucrose, Methyl Cellulose, Gelatin.

- **Lubricants**

Lubricants ensure a smooth surface on the dosage form by decreasing friction between the tablet walls and the die cavity during ejection.

Example: - Oils, Graphite, Dry Lubricant

- **Polymers**

Polymer is a natural or synthetic material containing large molecules made by Bonding (Chemical Linking) a series of building blocks called monomers the term polymer derived from the Greek word polus, meaning “Many and Meros” meaning “Part”.

They are widely used in drug delivery because to their distinct features that no other material can match. Polymers are employed to modulate medication release rates, stabilize formulations, mask flavor, and provide protection during oral drug delivery. Polymers can bind particles in solid dosage forms and alter liquid flow characteristics. [3]

Polymers are becoming increasingly relevant in the medication delivery industry. Polymers are the primary instrument for controlling the rate at which drugs are released from formulations. Polymers can be used to conceal the taste of drugs, improve their stability, and change their release properties. Biodegradable materials are employed in medicine and other applications. In recent years, the use of biodegradable polymers has increased. Biodegradable polymers are divided into two categories:

Synthetic and Natural Polymers

Natural polymers provide limited advantages over manufactured polymers. Although polymers are widely utilized in pharmaceutical packaging, this review focuses on the use of polymers in the formulation of various dosage forms.

- **Nature of Polymer:** Hydrophobic Polymer:- Ethyl Cellulose, Polydiethyl Siloxane Hydrophilic Polymer :- Cellulosic: MC, HPMC, HPC, HEC, NACMC. Cellulosic: Sodium Alginate, Xanthun Gum,

Synthetic polymers human-made materials that are made from repeated units of chemical building blocks called monomers. They are also known as plastics.

Example: - Nylon, Polyethylene, Polyester, Teflon, and Epoxy.

Polymers function in medicine delivery includes: Instant release dosage forms

- Tablets: Before tableting, polymers such as polyvinylpyrrolidone and hydroxypropyl methylcellulose (HPMC) are used as binders to help produce granules that enhance the flow and compaction characteristics of tablet formulations.
- Capsules: Many of the polymeric excipients used in immediate release tablets are also utilized to “bulk out” capsule fills. Gelatine is nearly always utilized as a shell material for both soft (one-piece) and hard (two-piece) capsules. Recently, HPMC has been created and approved as a substitute material for hard (two-piece) capsule production.

Advantages and disadvantages of CDDS

Advantages	Disadvantages
Controlled or defined drug release	Possible toxicity of material used
Target specify	Dose dumping
Long residence	Invasive procedure to implant or remove the system
Protection from metabolism by enzyme	Premature metabolism of the drug
Improved bioavailability	Uptake by RES reduce efficacy
Low dosing frequency	Poorer IVIVC
Flexibility in design	Need of advance technology
Reduction in dose size	Multiple formulation steps

Pharmacokinetics of Drug Delivery Systems Pharmacokinetics is the study of how pharmaceuticals travel into, though, and out of the body, including absorption, distribution, metabolism, and excretion. Simply put, it is what the body does with a drug. [4]



Figure 1: Pharmacokinetics of drug

Absorption

Absorption is the process by which a medicine moves from the site of administration to the bloodstream. Several factors influence the rate and amount of drug absorption, including the method of administration, physicochemical qualities of the drug, formulation type, and drug-food interactions. [4,5]

- **Passive Transport:** The transportation of a drug across a cell membrane from a high drug concentration location (such as the gastrointestinal tract) to a low drug concentration region (such as the bloodstream). This is a passive process that requires no energy; the rate of drug diffusion is proportional to the concentration gradient. [6]



Figure 2: Transport of Drug

- **Active Transport:** Active transport necessitates energy to enable drug molecules' transit against a concentration gradient, which typically happens at specific places in the small intestine The majority of medications that are absorbed via active transport have a similar structure to endogenous molecules such as ions, vitamins, carbohydrates, and amino acids. [6]

Distribution

Distribution is the reversible transfer of a drug between the circulation and the body's extravascular fluids and tissues (such as fat, muscle, and brain tissue). Drug distribution determines the amount of drug that reaches target locations in comparison to the rest of the body, and hence influences drug efficacy and toxicity Blood flow, the medication's lipophilicity and moleculer size, and its binding affinity with plasma protiens. [7,8]



Figure 3: Schematic of Barriers to Drug Distribution

Metabolism: Drugs are metabolized (in the gut wall and liver) into inactive or less active components before they enter the systemic circulation. A drug's concentration, particularly after oral delivery, is dramatically lowered before it enters the bloodstream. [8,9]



Figure 4: Schematic of Drug Metabolism in the Liver as well as the Cells

Excretion

Drug excretion is the process by which unmodified drugs or metabolites leave the body. [10] There are numerous distinct routes of excretion, including urine, bile, perspiration, saliva, tears, milk, and stool. [5]



Figure 5: Schematic Illustration of Drug Excretion from the Body

➢ **Bioavailability**

This is the fraction or percentage of the administered medicine that is absorbed into the systemic circulation. Drugs with high hepatic metabolism and rapid excretion have a limited bioavailability. The IV route offers 100% bioavailability. [11,12]



Figure 6: Schematic of Factors Accountable for the Reduction in Bioavailability

Biological half-life (t1/2).

The elimination half-life, also known as the biological half-life (t1/2), is the time at which the mass of an unaltered medication is reduced to half of its initial concentration. Simply put, t1/2 is the time it takes for half of an administered dose to be digested and removed from the bloodstream. [13]

Pharmacodynamic Properties of the Drug:

- **Therapeutic range:** For a controlled release drug delivery system, a drug's therapeutic range should be large enough that any modification in the release rate does not result in concentrations over this level.
- **therapeutic index:** The most often used statistic for determining a drug's margin of safety. Therapeutic index = TD50/ED50.The longer the therapeutic index, the safer the medicine. A medication is considered safe if its therapeutic index value exceeds 10.
- **Plasma concentration-response relationship:** Drugs like reserpine have pharmacological activity that is independent of concentration, making them poor candidates for controlled-release systems.

Classification of controlled drug delivery systems

Controlled release. Drug delivery systems are characterized according to the mechanism of drug release from the dosage form: dissolution-controlled, diffusion-controlled, water penetration-controlled (osmotic pressure-controlled and swelling-controlled), chemically controlled, and nanoparticle-based. [14]

- **Dissolution Controlled Drug Delivery Systems**

Drugs in dissolution-controlled release systems are either coated with or contained in slowly dissolving polymeric membranes (reservoir systems) or matrices (monolithic system). [15]

In reservoir systems, pharmaceuticals are protected by low-solubility polymeric membranes. The majority of conventional immediate-release tablets, pills, and effervescent tablets are dissolution-controlled systems, with dissolving being the rate-limiting phase.

- **Diffusion-Controlled Drug Delivery System**

Diffusion-controlled release systems capture pharmaceuticals and release them through inert water-insoluble polymeric membranes (reservoir systems) or polymeric matrices (monolithic systems). These are characterized as membrane control reservoir systems or monolithic matrix systems. [16,17]

Diffusion-controlled systems are classified into

- Membrane-controlled and monolithic or matrix systems.

In membrane-controlled systems, the medicine is held in the core as a reservoir and protected by a thin polymeric membrane. The membrane can be either porous or non porous. Encapsulation and tablet press coating are two common ways for fabricating membrane-controlled reservoir systems [16]



Figure 7: Membrane Controlled Drug Delivery Systems

➢ **Water Penetration Controlled Drug Delivery Systems**

These are classified as osmotic pressure-controlled medication delivery systems or swelling-controlled drug delivery systems. The rate control is determined by the amount of water entering the system.

Osmotic controlled drug delivery systems and swelling controlled drug delivery system

- **Osmotic Controlled Drug Delivery Systems**

Employs osmotic pressure to deliver medications in a controlled manner utilizing osmogens. Osmosis is the process of moving solvent from a lower concentration of solute to a greater concentration of solute across a semipermeable membrane. These systems can be used for both routes of administration, i.e., oral and injectables. [18]



Figure 8: Schematic of Osmotic Pressure CDDS

➢ **Swelling-Controlled Drug Delivery Systems,**

The medication is disseminated or dissolved in the hydrophilic polymer when it is glassy. In an aqueous solution, water penetrates the matrix, lowering the polymer's glass transition temperature below ambient. [19]



Figure 9: Mechanism of Drug Release from the Swelling CDDS

➢ **Chemically Controlled Drug Delivery Systems**

Chemically controlled delivery systems change their chemical structure when exposed to the biological milieu. These are made of biodegradable polymers which degrade in the body as a result of natural biological processes, eliminating the need to remove the delivery system after exhausting an active agent from the system.

Several factors influence deterioration (bioerosion and bulk erosion), including chemical structure and content, the existence of unexpected units or chain flaws, configuration, and molecular weight. [20]

➢ **Factors Influencing the Design and Performance of Controlled Drug Delivery Systems. The Biopharmaceutical Description of Drugs**

- **Molecular Weight of the Medication.**

Because passive diffusion accounts for more than 95% of medicine absorption, reduced molecular weight increases absorption speed and completeness.

A drug's diffusivity, which is inversely proportional to molecule size, reflects its ability to pass

through membranes.

- **Aqueous Solubility of the Medication**

Drugs must be soluble in order to be absorbed, and compounds with extremely low water solubility typically have issues with oral bioavailability.

This is due to the reduced solubility at the absorption site and the shorter gastrointestinal transit time of undissolved drug particles.

- **Partition Coefficient**

Drugs absorbed through passive diffusion must have a minimum Area of Polar Character (APC). Many drugs, particularly in an n-octanol/buffer system, have a greater APC. It is necessary to determine the APC over the pH range of the gastrointestinal tract.

- **pKa and Ionization at Physiological PH**

To facilitate optimal passive absorption, drugs should largely exist at the absorption site in a non-ionized state, often between 0.1 and 5%.

- **Medicinal Stability**

Drugs that are stable in acid/base conditions, resistant to enzymatic degradation, and able to survive a variety of stomach fluids make good candidates for Controlled Release Drug Delivery Systems. [21]

Controlled release formulations should not be used for drugs that are prone to stomach and small intestine breakdown because this can drastically lower the drug's bioavailability.

Conventional vs. Controlled Drug Delivery Systems

Conventional DDS (tablets, capsules, syrups, etc.) are quickly removed from the body, and the dose is not properly controlled within the therapeutic window. After taking a single standard dose, the drug rapidly metabolizes and the drug level rises, followed by an exponential drop. The time range may be insufficient to create a meaningful therapeutic effect, leading to a sub-therapeutic response. demonstrates plasma drug changes in conventional DDS. Hence to maintain the plasma drug concentration above the minimum.

effective concentration and below the toxic concentration multiple approaches have been sought. Thus, controlled release DDS are required to keep plasma drug levels constant within the therapeutic window and provide the intended therapeutic impact over a longer period of time. [22]

Advantages and Disadvantages of Conventional Delivery Systems.

Advantages of Conventional DDS	Disadvantage of Conventional DDS
Higher shelf life	Premature metabolism of the drug
Convenience in administration	Poor absorption from site of administration
Accommodated patient variation	Poor bioavailability

Accurate and measured unit excretion from the body	Premature excretion from the body
Flexibility for physician to dose adjustment	Poor patient compliance

Applications

Controlled release formulas find applications in different medical fields. Chronic Conditions: Patients with chronic disorders such as diabetes, hypertension, asthma, and epilepsy benefit from controlled release drugs because they provide continuous drug delivery.

- **Neurological disorders:** Controlled release medications can help treat Alzheimer's, Parkinson's, and Attention Deficit Hyperactivity Disorder (ADHD).
- **Hormone therapy:** Controlled release formulations are used in hormone-based therapies, such as contraception, to provide hormones consistently and effectively.
- **Cardiovascular diseases:** CDDS can be used to deliver medications for hypertension, heart failure, and other cardiovascular problems. The regulated release ensures optimal medication levels over a longer period of time and improves patient compliance.
- **Antibiotic therapy:** Controlled drug delivery systems can be used to administer antibiotics to localized infections, such as in orthopedic implants, in order to prevent bacterial colonization and biofilm formation.
- **Psychiatric disorders**

Controlled release medications can stabilize mood and minimize fluctuations associated with immediate-release formulations for disorders such as bipolar disorder and schizophrenia.

Challenges and future Direction in Controlled Drug Delivery Systems:

Over the last two decades, regulated medication delivery technologies have advanced dramatically. Nonetheless, there is still room for improvement to overcome constraints and broaden future possibilities.

- **Nanomedicine Challenges and Improvements:**

Nano-drug delivery systems have emerged as a viable alternative to traditional delivery systems, offering various advantages such as focused medication delivery with increased efficacy. However, Nano particulate systems must be evaluated for safety and toxicity. In multiple investigations, nanoparticles resulted in uptake by the reticuloendothelial system and caused inflammation of the liver, lung, and brain due to the oxidative stress created by nanoparticles. [23]

The capacity of Nano carriers to permeate the blood-brain barrier is useful in brain illnesses; nevertheless, neurotoxicity occurs when the intended location of action is not the brain. Furthermore, nanoparticles can cause immunomodulatory effects in rare situations. [24]

The latest advancements in 3D printing offer customized individualized medication for higher therapeutic efficacy in customized medical devices, drug-eluting implants, and print lets (3D-printed tablets) with a tailored dose, shape, size, and release properties.

Nanomedicine uses nanotechnology technologies (biocompatible nanoparticles and Nano robots) to deliver medications, diagnose diseases, and perform in vivo imaging. Nanotechnology has enhanced medicine delivery by focusing on specific organs to maximize the efficacy and safety of individual drugs.

- **Microfluidics**:

Controlled Drug Delivery Microfluidics systems for implantable and controlled delivery are an intriguing area for future research. It is sometimes referred to as lab-on-a-chip (LOC) technology, which uses micro-devices with small chambers and channels. [25] These micro-devices control the flow of fluids, allowing the medicine to be delivered to a specific spot more efficiently.

- **Molecularly Imprinted Polymers (MIPs):**

Molecular imprinting polymers are cross-linked polymers with binding sites that are unique to each target molecule. These are cross-linked polymers with binding sites specific to the target molecule. [26] The molecularly imprinted polymers are composed of five components: the template, cross-linker, porogen, monomer, and initiator. The template aids in the selection of a functional monomer. It operates as an artificial receptor for target molecules and mimics the natural antibody-antigen systems. MIPs are excellent and prospective candidates for vaccine development and biologic drug delivery since their drug-target specificity is clear [27]



Figure 10: Molecular Imprinting Polymers Synthesis Protocol

Intelligent Biomaterials

There is a huge opportunity for the development of intelligent biomaterials that can sense and self-adapt to the environment while also controlling drug release, such as an intelligent hydrogel that can sense blood sugar levels in the surrounding environment (either pH or temperature) and deliver the specific dose of insulin required to maintain blood sugar levels. There is a demand for smaller hydrogels, however the existing problems in generating smaller biosensor hydrogels include their fragility and the inability to impart sufficient mechanical strength to fulfill the goal. [28]

- **CRISPR/CAS9-Based Systems:**

More recently, there has been an increase in interest in drug release based on CRISPR, or clustered regularly interspaced short palindromic repeats, which are a set of DNA sequences found primarily in prokaryotes and serve as an adaptive immune system effector. It has brought about revolutionary changes in the field of tissue-specific genes. [29]

- **Quantum Sensing Drug Delivery:**

Quantum Sensing for Drug Delivery Quantum dots, or QDs, are another technique that has helped to bridge the gap between nanotechnology and drug testing. These are basically semiconductors of carbon-based nanoparticles with strong chemical inertness, higher specific surface areas, lesser ability to impart toxicity, and higher solubility. [30]

- **Three-Dimensional Printing for Drug Delivery:**

Three-dimensional-printed drug delivery systems have sparked interest in tissue engineering and drug delivery due to its flexibility to be customized using numerous materials and their unprecedented capacity to print complex physiological structures and organs. The most recent advances in 3D printing provide customized, personalized medication for improved therapeutic efficacy in customized medical devices, drug-eluting implants, and printlets (3D-printed tablets) with tailored dose, shape, size, and release characteristics [31,32]

Conclusion

The dose form consists of medicines and excipients. Excipients are used to add structure, improve stability, and hide taste. Solid, semisolid, and liquid dosage forms are the traditional dosage forms that suffer from changes in plasma drug levels, necessitating high dose and dosing frequency with low patient compliance. The bioavailability of a medicine is critical for attaining the desired effect from any dosage form. Controlled drug delivery systems have developed as a viable alternative to traditional methods for improving bioavailability, extending drug release, and maintaining medication plasma levels within the therapeutic window with minimal adverse effects.

Controlled drug delivery systems have transformed the way therapeutic drugs are delivered, making them indispensable tools in modern pharmacotherapy. These systems are designed to manage drug release, ensuring the best therapeutic results while minimizing side effects. One well-known form is sustained release systems, which minimize the frequency of doses while increasing patient adherence by gradually releasing drugs over time. Another advancement is targeted drug delivery, which allows drugs to be administered directly to the site of action. This accuracy addresses a long-standing issue in traditional medication delivery by reducing injury to healthy tissues while enhancing therapeutic efficacy.

REFERENCES

[1] Langer, R. Drug delivery and targeting. Nature 1998, 392, 5–10.

[2] Chaudhari S.P., Patil P.S. Pharmaceutical excipients: A review. IJAPBC. 2012;1:21–34.

[3] Aggarwal S, Goel A, Singla S, Drug Delivary: Special Emphasis Given On Bioderadable Polymers, Advances in Polymer Science and Technology: An International Journal, 2012, 2(1), 1-15

[4] Shargel, L.; Andrew, B.; Wu-Pong, S. Applied Biopharmaceutics & Pharmacokinetics; Appleton & Lange Stamford: Stamford, UK, 1999; Volume 264.

[5] Jambhekar, S.S.; Breen, P.J. Basic Pharmacokinetics; Pharmaceutical Press: London, UK, 2009; Volume 76.

[6] Obata, K.; Sugano, K.; Saitoh, R.; Higashida, A.; Nabuchi, Y.; Machida, M.; Aso, Y. Prediction of oral drug absorption in humans by theoretical passive absorption model. Int. J. Pharm. 2005, 293, 183–192.

[7] Seydel, J.K.; Wiese, M. Drug-Membrane Interactions: Analysis, Drug Distribution, Modeling; John Wiley & Sons: Hoboken, NJ, USA, 2009; Volume 15.

[8] Gillette, J.R. Factors affecting drug metabolism. Ann. N. Y. Acad. Sci. 1971, 179, 43–66.

[9] Ekins, S.; Ring, B.J.; Grace, J.; McRobie-Belle, D.J.; Wrighton, S.A. Present and future in vitro approaches for drug metabolism. J. Pharmacol. Toxicol. Methods 2000, 44, 313–324.

[10] Taft, D.R. Drug excretion. In Pharmacology; Elsevier: Amsterdam, The Netherlands, 2009; pp. 175–199

[11] Reinberg, A.E. Concepts of circadian chronopharmacology. Ann. N. Y. Acad. Sci. 1991, 618, 102–115.

[12] Prabu, S.L.; Suriyaprakash, T.; Ruckmani, K.; Thirumurugan, R. Biopharmaceutics and Pharmacokinetics. In Basic Pharmacokinetic Concepts and Some Clinical Applications; IntechOpen: London, UK, 2015.

[13] Hallare, J.; Gerriets, V. Half Life; StatPearls Publishing LLC: Treasure Island, FL, USA, 2020

[14] Gupta, B.P.; Thakur, N.; Jain, N.P.; Banweer, J.; Jain, S. Osmotically controlled drug delivery system with associated drugs. J. Pharm. Pharm. Sci. 2010, 13, 571–588.

[15] Wang, Z.; Shmeis, R.A. Dissolution controlled drug delivery systems. Des. Control. Release Drug Deliv. Systems. 2006, 139–172

[16] Siepmann, J.; Siegel, R.A.; Siepmann, F. Diffusion controlled drug delivery systems. In Fundamentals and Applications of Controlled Release Drug Delivery; Springer: Berlin/Heidelberg, Germany, 2012; pp. 127–152.

[17] Siepmann, J.; Siepmann, F. Modeling of diffusion controlled drug delivery. J. Control. Release 2012, 161, 351–362

[18] Srikonda, S.; Kotamraj, P.; Barclay, B. Osmotic controlled drug delivery systems. Des. Control. Release Drug Deliv. Syst. 2006, 1, 203.

[19] Siepmann, J.; Siepmann, F. Swelling controlled drug delivery systems. In Fundamentals and Applications of Controlled Release Drug Delivery; Springer: Berlin/Heidelberg, Germany, 2012; pp. 153–170.

[20] Kopeček, J. Polymer–drug conjugates: Origins, progress to date and future directions. Adv. Drug Deliv. Rev. 2013, 65, 49–59.

[21] Michal J. Rathbone, J. Hadgraft, M. Roberts, 2nd edition, Modified-Release Drug Delivery Technology, 2012, PP. 567-578.

[22] Hardenia, A.; Maheshwari, N.; Hardenia, S.S.; Dwivedi, S.K.; Maheshwari, R.; Tekade, R.K. Scientific rationale for designing controlled drug delivery systems. In Basic Fundamentals of Drug Delivery; Elsevier: Amsterdam, The Netherlands, 2019; pp. 1–28.

[23] Bartucci, R.; Paramanandana, A.; Boersma, Y.L.; Olinga, P.; Salvati, A. Comparative study of nanoparticle uptake and impact in murine lung, liver and kidney tissue slices. Nanotoxicology 2020, 14, 847–865.

[24] Lu, L.; Qi, S.; Chen, Y.; Luo, H.; Huang, S.; Yu, X.; Luo, Q.; Zhang, Z. Targeted immunomodulation of inflammatory monocytes across the blood-brain barrier by curcumin-loaded nanoparticles delays the progression of experimental autoimmune encephalomyelitis. Biomaterials 2020, 245, 119987.

[25] Hassan, S.; Zhang, Y.S. Chapter 10—Microfluidic technologies for local drug delivery. In Microfluidics for Pharmaceutical Applications; Santos, H.A., Liu, D., Zhang, H., Eds.; William Andrew Publishing: Amsterdam, The Netherlands, 2019; pp. 281–305.

[26] Zaidi, S.A. Molecular imprinting: A useful approach for drug delivery. Mater. Sci. Energy Technol. 2020, 3, 72–77.

[27] Saylan, Y.; Akgönüllü, S.; Yavuz, H.; Ünal, S.; Denizli, A. Molecularly imprinted polymer based sensors for

medical applications. Sensors 2019, 19, 1279.

[28] Mogoşanu, G.D.; Grumezescu, A.M.; Bejenaru, L.E.; Bejenaru, C. Chapter 8—Natural and synthetic polymers for drug delivery and targeting. In Nanobiomaterials in Drug Delivery; Grumezescu, A.M., Ed.; William Andrew Publishing: Amsterdam, The Netherlands, 2016; pp. 229–284.

[29] Wei, T.; Cheng, Q.; Min, Y.-L.; Olson, E.N.; Siegwart, D.J. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat. Commun. 2020, 11, 3232.

[30] Subham Jain, N.; Preeti, S.; Amit, B.P. Application of Quantum Dots in Drug Delivery. Nanosci. Nanotechnol. Asia 2021, 11, 1–16.

[31] Beg, S.; Almalki, W.H.; Malik, A.; Farhan, M.; Aatif, M.; Alharbi, K.S.; Alruwaili, N.K.; Alrobaian, M.; Tarique, M.; Rahman, M. 3D printing for drug delivery and biomedical applications. Drug Discov. Today 2020, 25, 1668–1681.

[32] Trenfield, S.J.; Awad, A.; Madla, C.M.; Hatton, G.B.; Firth, J.; Goyanes, A.; Gaisford, S.; Basit, A.W. Shaping the future: Recent advances of 3D printing in drug delivery and healthcare. Expert Opin. Drug Deliv. 2019, 16, 1081–1094.